Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases

Plus Therapeutics, Inc. (NASDAQ: PSTV) has spotlighted strong clinical results from its ReSPECT-LM Phase 1 trial of REYOBIQ, an investigational radiotherapeutic targeting leptomeningeal metastases (LM), a rare and aggressive cancer complication affecting the membranes of the brain and spinal cord. The announcement coincided with the company’s presentations at the Society for Immunotherapy of Cancer (SITC) 40th annual meeting and the Melanoma Research Foundation’s Brain Metastases Summit 4.0, drawing heightened investor and clinical interest in the biotech’s expanding neuro-oncology portfolio.

The early data showed that REYOBIQ achieved a >75 percent clinical benefit rate across efficacy endpoints, including measurable reductions in circulating tumor cells (CTCs) and RNA-sequencing biomarkers associated with tumor cell death. Notably, no dose-limiting toxicities (DLTs) were observed up to the recommended Phase 2 dose of 44.1 mCi, signaling a favorable safety profile for a patient population that typically faces a median survival of just two to six months.

How Plus Therapeutics is redefining treatment potential in leptomeningeal metastases through radiotherapeutic precision

Leptomeningeal metastases remain one of oncology’s most intractable conditions, often representing the final stage of cancer spread in breast, lung, and melanoma patients. There are currently no FDA-approved therapies specifically indicated for LM, leaving patients reliant on palliative radiation or intrathecal chemotherapy that offers limited efficacy and significant systemic toxicity. Against this backdrop, Plus Therapeutics’ ReSPECT-LM program marks one of the few clinical efforts seeking to establish a disease-modifying treatment through localized radiopharmaceutical delivery.

REYOBIQ (rhenium-186 obisbemeda) uses a targeted convection-enhanced delivery system designed to administer beta radiation directly into the cerebrospinal fluid (CSF), maximizing tumor exposure while minimizing damage to healthy tissue. This approach enables continuous, image-guided administration within the central nervous system (CNS), a region traditionally resistant to systemic drugs due to the blood-brain barrier.

At SITC 2025, the company’s data emphasized that REYOBIQ not only achieved measurable responses but also produced a dose-response correlation in CTC reduction and immune-activation markers, indicating both direct tumor impact and potential immune-modulatory benefits. The presentations were viewed by attending oncologists as a validation of Plus Therapeutics’ hypothesis that precision-delivered radiotherapeutics could transform the LM landscape—particularly if expanded multi-dose and combination trials reproduce similar outcomes.

Why investor sentiment toward Plus Therapeutics is shifting despite its micro-cap valuation

In the capital markets, Plus Therapeutics’ announcement acted as a catalyst for renewed attention toward PSTV, which had long traded as a micro-cap biotech under US $50 million in market capitalization. Investor sentiment on retail platforms such as StockTwits and Seeking Alpha reflected cautious optimism, with traders noting that the absence of DLTs and a >75 percent benefit rate represented an inflection point for an otherwise overlooked radiopharma developer.

The company’s share performance showed mild volatility immediately following the release, with a modest intraday surge tempered by profit-taking typical of small-cap biotechs after clinical catalysts. Analysts observing the stock from a technical perspective cited potential upside if the ReSPECT-LM program proceeds into a Phase 2 study under the FDA’s Fast Track and Orphan Drug designations.

The broader investment case for Plus Therapeutics is also tied to its non-dilutive funding base. The firm continues to benefit from a US $17.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)—a critical differentiator in a market where early-stage developers often rely on equity dilution. The grant supports both ReSPECT-LM and the ReSPECT-GBM study in recurrent glioblastoma, another notoriously treatment-resistant brain cancer.

Institutional sentiment remains restrained, however, reflecting a consensus that clinical data—though encouraging—remain preliminary. Market participants continue to assess Plus Therapeutics through the lens of binary risk typical of radiopharmaceutical innovators: one meaningful clinical success could catalyze substantial valuation re-rating, while regulatory or safety setbacks could rapidly erode speculative interest.

How Plus Therapeutics positions REYOBIQ within a diversified CNS-focused pipeline

The ReSPECT-LM trial sits within a triad of CNS-directed programs advancing under the REYOBIQ platform. Alongside ReSPECT-LM for leptomeningeal metastases, the company is conducting ReSPECT-GBM for recurrent glioblastoma and ReSPECT-PBC for pediatric brain cancer. Each utilizes the same rhenium-186 isotope complex but optimized delivery protocols tailored to tumor location and patient profile.

Management has described REYOBIQ as a “next-generation, image-guided beta-emitting radiotherapeutic,” integrating both diagnostic and therapeutic imaging modalities—a concept sometimes referred to as theranostics. By pairing high-resolution imaging with localized delivery, Plus Therapeutics aims to create a scalable CNS platform that can be adapted for other compartmentalized malignancies, including intraventricular or spinal metastases.

At the Melanoma Research Foundation’s Brain Metastases Summit 4.0, oncology specialists highlighted that the targeted approach of REYOBIQ could complement immunotherapy or checkpoint inhibitors in resistant disease, particularly given evidence of radiation-induced immune sensitization. Clinical investigators reportedly noted that the ability to visualize distribution through single-photon emission computed tomography (SPECT) gives REYOBIQ a pharmacokinetic advantage rarely achievable in CNS therapeutics.

The FDA’s dual Fast Track and Orphan Drug designations underscore regulatory recognition of the therapy’s potential to address an unmet need. These designations not only streamline review timelines but also provide seven years of post-approval exclusivity in the U.S., enhancing commercial viability should efficacy be confirmed in subsequent trials.

What these results could mean for patients and the evolving radiopharmaceutical market

From a clinical standpoint, Plus Therapeutics’ ReSPECT-LM data inject renewed hope into a field long constrained by the blood-brain barrier and the limited permeability of cytotoxic agents. The >75 percent clinical benefit rate observed in this early cohort represents an encouraging early marker, though oncology researchers caution that long-term survival and quality-of-life outcomes remain to be validated in multi-dose and randomized settings.

The broader radiopharmaceutical industry has entered a phase of rapid expansion, driven by growing demand for targeted radiation treatments that minimize systemic toxicity. Global analysts project the radiotherapeutics market to exceed US $15 billion by 2030, with CNS-specific indications representing one of the least saturated sub-segments. Plus Therapeutics’ proprietary rhenium-186 technology could therefore position the company as a niche leader in this high-barrier-to-entry domain.

In discussions with oncology stakeholders, attendees at SITC 2025 suggested that the trial’s early efficacy and tolerability data may justify adaptive trial designs moving forward, potentially accelerating timelines toward pivotal evaluation. The company is expected to pursue an expanded cohort in 2026 that could inform regulatory interactions for a Phase 2 registration-enabling study.

If REYOBIQ demonstrates consistent benefit in subsequent trials, Plus Therapeutics could pioneer the first approved therapy for leptomeningeal metastases—transforming an orphan indication into a commercial foothold within CNS oncology. That potential, coupled with strong safety data, has already begun to shift market sentiment, suggesting that investors are now reassessing PSTV less as a speculative penny stock and more as a credible emerging player in precision radiotherapeutics.

How regulatory designations and future milestones could shape Plus Therapeutics’ commercial trajectory

Plus Therapeutics’ near-term milestones include its poster and oral presentations at the SITC annual meeting and MRF Brain Metastases Summit between November 8 and 10 in Alexandria, Virginia, where clinicians will review detailed radiographic and biomarker analyses. The company has also indicated that enrollment for its ReSPECT-LM dose-optimization trial is proceeding on schedule, with further safety and survival data expected in early 2026.

Regulatory dialogue with the U.S. Food and Drug Administration is expected to intensify once those updates are available, particularly regarding potential Breakthrough Therapy designation or adaptive approval frameworks. Given the FDA’s growing openness to radiopharmaceuticals for rare cancers—evidenced by recent approvals in neuroendocrine and prostate malignancies—Plus Therapeutics’ LM focus aligns closely with emerging agency priorities.

From a strategic perspective, the company’s combination of technical differentiation, non-dilutive funding, and early regulatory traction sets it apart in a competitive biotech market increasingly driven by precision oncology narratives. If subsequent studies validate efficacy across larger cohorts, Plus Therapeutics could become a takeover target for major radiopharma consolidators seeking CNS pipeline exposure.

While commercialization is still several years away, the convergence of positive safety data, early efficacy signals, and supportive regulatory mechanisms is fueling optimism that REYOBIQ may eventually redefine the treatment paradigm for leptomeningeal metastases.